WASHINGTON, Nov. 25, 2014 (GLOBE NEWSWIRE) -- REGENXBIO Inc. today announced that Ken Mills, President and Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, December 2, 2014 at 2:50 p.m. EST.
REGENXBIO Inc. is the leading next-generation AAV gene therapy company, developing a new class of personalized therapies based on its proprietary NAV® Technology platform for a range of severe diseases with serious unmet needs. NAV Technology includes novel AAV vectors AAV7, AAV8, AAV9, and AAVrh10. The company is developing gene therapy treatments to address lysosomal storage disorders and ocular diseases. REGENXBIO has enabled leading global partners including Baxter Healthcare, Fondazione Telethon, Audentes Therapeutics, Lysogene, Esteve, AveXis, AAVLife and Voyager Therapeutics to use its NAV Technology. In addition, together with Fidelity Biosciences, REGENXBIO formed Dimension Therapeutics, a company focused on the development and commercialization of NAV-based gene therapies for rare diseases.
For more information about REGENXBIO, please visit www.regenxbio.com.